Sangamo Therapeutics' (SGMO) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO - Free Report) in a report published on Monday morning,Benzinga reports. They currently have a $10.00 price objective on the biopharmaceutical company's stock. HC Wainwright also issued estimates for Sangamo Therapeutics' Q4 2024 earnings at ($0.11) EPS, FY2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.08) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at ($0.02) EPS, FY2028 earnings at $0.19 EPS and FY2029 earnings at $0.42 EPS.

Several other equities analysts have also recently commented on SGMO. StockNews.com cut shares of Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday, December 24th. Wells Fargo & Company reduced their target price on Sangamo Therapeutics from $3.00 to $2.00 and set an "equal weight" rating on the stock in a report on Tuesday, December 31st. Truist Financial decreased their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. Jefferies Financial Group dropped their price target on Sangamo Therapeutics from $7.00 to $3.00 and set a "buy" rating on the stock in a research report on Tuesday, December 31st. Finally, Barclays lifted their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an "overweight" rating in a report on Thursday, November 14th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Sangamo Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $5.17.

Sangamo Therapeutics Price Performance

SGMO stock remained flat at $1.23 during midday trading on Monday. The company's stock had a trading volume of 4,021,222 shares, compared to its average volume of 5,829,853. The business has a 50-day moving average of $1.74 and a 200 day moving average of $1.33. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.18. The firm has a market capitalization of $256.64 million, a PE ratio of -1.64 and a beta of 1.29.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. The business had revenue of $49.41 million during the quarter, compared to analyst estimates of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same quarter in the previous year, the firm earned ($0.34) earnings per share. On average, sell-side analysts forecast that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Shelton Wealth Management LLC bought a new stake in shares of Sangamo Therapeutics during the fourth quarter valued at approximately $29,000. Sageworth Trust Co acquired a new position in Sangamo Therapeutics during the 4th quarter valued at about $61,000. Meritage Portfolio Management raised its holdings in Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 6,740 shares in the last quarter. XTX Topco Ltd boosted its stake in Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company's stock valued at $90,000 after purchasing an additional 64,981 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company's stock valued at $94,000 after purchasing an additional 38,850 shares during the period. Institutional investors and hedge funds own 56.93% of the company's stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.